PTHLH and hypercalcemia disease: Dysregulation of systemic Ca2+ homeostasis, especially in patients with high-grade tumors, is common, due to increased secretion of PTHrP and the development of co-morbidities such as cancer-induced hypercalcemia (CIH) (7, 49–53).